… comparisons of pharmacologic agents for the treatment of PAH, and because of their different
desirable and undesirable effects for patients, we recommend that drug therapy be chosen …

… an update on the most recently published treatment guidelines for pharmacologic treatment
of PAH and incorporates them into a contemporary approach to the treatment of this disease. …

… Pulmonary arterial hypertension (PAH) is a rare but complex chronic disease of the …
Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert …

… Current treatment consists of combination drug therapy that targets more than 1 biological
… Practice guidelines recommend obtaining an echocardiogram in all patients with portal …

… The newest drug approved for the treatment of PAH, selexipag, targets the prostacyclin
pathway by selectively … ESC/ERS Guidelines for the diagnosis and treatment of pulmonary …

… guidelines and collective clinical experiences to navigate between pharmacologic and
interventional treatments, … techniques, non-pharmacologic therapies discussed in this section are …

… of pulmonary arterial hypertension that resulted in initiation of intravenous or subcutaneous
prostanoid therapy or the need for lung … of 3 novel PAH drug therapies: the SERAPHIN trial (…

… pulmonary arterial hypertension (PAH). These recommendations were built on the 2015
European Pulmonary Hypertension guidelines … combination therapy and the higher risk of drug-…

… Pulmonary arterial hypertension pharmacotherapies by … Sotatercept is not US Food and
Drug Administration–approved; it … ERS guidelines for the diagnosis and treatment of pulmonary …

… Idiopathic PAH (IPAH) still has a poor prognosis despite advances in drug therapy that
target the endothelin, nitric oxide, and prostacyclin pathways. Right heart failure is the most …